TISIDB

Summary
Symbol	NFKB2
Name	nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100)
Aliases	LYT-10; NF-kB2; CVID10; H2TF1; LYT10; DNA-binding factor KBF2; NFKB, p52/p100 subunit; lymphocyte translocat ......
Chromosomal Location	10q24
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus. Cytoplasm. Note=Nuclear, but also found in the cytoplasm in an inactive form complexed to an inhibitor (I-kappa-B).
Domain	PF12796 Ankyrin repeats (3 copies) PF00531 Death domain PF16179 Rel homology dimerisation domain PF00554 Rel homology DNA-binding domain
Function	NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. In a non-canonical activation pathway, the MAP3K14-activated CHUK/IKKA homodimer phosphorylates NFKB2/p100 associated with RelB, inducing its proteolytic processing to NFKB2/p52 and the formation of NF-kappa-B RelB-p52 complexes. The NF-kappa-B heterodimeric RelB-p52 complex is a transcriptional activator. The NF-kappa-B p52-p52 homodimer is a transcriptional repressor. NFKB2 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p100 and generation of p52 by a cotranslational processing. The proteasome-mediated process ensures the production of both p52 and p100 and preserves their independent function. p52 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. p52 and p100 are respectively the minor and major form; the processing of p100 being relatively poor. Isoform p49 is a subunit of the NF-kappa-B protein complex, which stimulates the HIV enhancer in synergy with p65. In concert with RELB, regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK-ARNTL/BMAL1 heterodimer.

> Gene Ontology [ TOP ]
Biological Process	GO:0001819 positive regulation of cytokine production GO:0002237 response to molecule of bacterial origin GO:0002250 adaptive immune response GO:0002266 follicular dendritic cell activation GO:0002268 follicular dendritic cell differentiation GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains GO:0002467 germinal center formation GO:0007249 I-kappaB kinase/NF-kappaB signaling GO:0007568 aging GO:0030198 extracellular matrix organization GO:0032479 regulation of type I interferon production GO:0032481 positive regulation of type I interferon production GO:0032496 response to lipopolysaccharide GO:0032606 type I interferon production GO:0038061 NIK/NF-kappaB signaling GO:0043062 extracellular structure organization GO:0048511 rhythmic process GO:0048536 spleen development GO:0051090 regulation of sequence-specific DNA binding transcription factor activity GO:0051091 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051092 positive regulation of NF-kappaB transcription factor activity
Molecular Function	GO:0000978 RNA polymerase II core promoter proximal region sequence-specific DNA binding GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding GO:0000987 core promoter proximal region sequence-specific DNA binding GO:0001077 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding GO:0001159 core promoter proximal region DNA binding GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding GO:0003682 chromatin binding GO:0003713 transcription coactivator activity
Cellular Component	GO:0033256 I-kappaB/NF-kappaB complex GO:0033257 Bcl3/NF-kappaB2 complex

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04010 MAPK signaling pathway hsa04064 NF-kappa B signaling pathway hsa04380 Osteoclast differentiation
Reactome	R-HSA-166054: Activated TLR4 signalling R-HSA-5621481: C-type lectin receptors (CLRs) R-HSA-5607764: CLEC7A (Dectin-1) signaling R-HSA-3247509: Chromatin modifying enzymes R-HSA-4839726: Chromatin organization R-HSA-1280215: Cytokine Signaling in Immune system R-HSA-1834949: Cytosolic sensors of pathogen-associated DNA R-HSA-3134963: DEx/H-box helicases activate type I IFN and inflammatory cytokines production R-HSA-5607761: Dectin-1 mediated noncanonical NF-kB signaling R-HSA-1643685: Disease R-HSA-5602358: Diseases associated with the TLR signaling cascade R-HSA-5260271: Diseases of Immune System R-HSA-5603027: IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR) R-HSA-5603029: IkBA variant leads to EDA-ID R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-448706: Interleukin-1 processing R-HSA-975871: MyD88 cascade initiated on plasma membrane R-HSA-975155: MyD88 dependent cascade initiated on endosome R-HSA-166166: MyD88-independent TLR3/TLR4 cascade R-HSA-166058: MyD88 R-HSA-5676590: NIK-->noncanonical NF-kB signaling R-HSA-3214841: PKMTs methylate histone lysines R-HSA-168928: RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways R-HSA-1810476: RIP-mediated NFkB activation via ZBP1 R-HSA-449147: Signaling by Interleukins R-HSA-445989: TAK1 activates NFkB by phosphorylation and activation of IKKs complex R-HSA-5668541: TNFR2 non-canonical NF-kB pathway R-HSA-168180: TRAF6 Mediated Induction of proinflammatory cytokines R-HSA-933542: TRAF6 mediated NF-kB activation R-HSA-975138: TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation R-HSA-937061: TRIF-mediated TLR3/TLR4 signaling R-HSA-168142: Toll Like Receptor 10 (TLR10) Cascade R-HSA-181438: Toll Like Receptor 2 (TLR2) Cascade R-HSA-168164: Toll Like Receptor 3 (TLR3) Cascade R-HSA-166016: Toll Like Receptor 4 (TLR4) Cascade R-HSA-168176: Toll Like Receptor 5 (TLR5) Cascade R-HSA-168181: Toll Like Receptor 7/8 (TLR7/8) Cascade R-HSA-168138: Toll Like Receptor 9 (TLR9) Cascade R-HSA-168179: Toll Like Receptor TLR1 R-HSA-168188: Toll Like Receptor TLR6 R-HSA-168898: Toll-Like Receptors Cascades R-HSA-1606322: ZBP1(DAI) mediated induction of type I IFNs

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04010 MAPK signaling pathway
hsa04064 NF-kappa B signaling pathway
hsa04380 Osteoclast differentiation

Reactome

R-HSA-166054: Activated TLR4 signalling
R-HSA-5621481: C-type lectin receptors (CLRs)
R-HSA-5607764: CLEC7A (Dectin-1) signaling
R-HSA-3247509: Chromatin modifying enzymes
R-HSA-4839726: Chromatin organization
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-1834949: Cytosolic sensors of pathogen-associated DNA
R-HSA-3134963: DEx/H-box helicases activate type I IFN and inflammatory cytokines production
R-HSA-5607761: Dectin-1 mediated noncanonical NF-kB signaling
R-HSA-1643685: Disease
R-HSA-5602358: Diseases associated with the TLR signaling cascade
R-HSA-5260271: Diseases of Immune System
R-HSA-5603027: IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR)
R-HSA-5603029: IkBA variant leads to EDA-ID
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-448706: Interleukin-1 processing
R-HSA-975871: MyD88 cascade initiated on plasma membrane
R-HSA-975155: MyD88 dependent cascade initiated on endosome
R-HSA-166166: MyD88-independent TLR3/TLR4 cascade
R-HSA-166058: MyD88
R-HSA-5676590: NIK-->noncanonical NF-kB signaling
R-HSA-3214841: PKMTs methylate histone lysines
R-HSA-168928: RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
R-HSA-1810476: RIP-mediated NFkB activation via ZBP1
R-HSA-449147: Signaling by Interleukins
R-HSA-445989: TAK1 activates NFkB by phosphorylation and activation of IKKs complex
R-HSA-5668541: TNFR2 non-canonical NF-kB pathway
R-HSA-168180: TRAF6 Mediated Induction of proinflammatory cytokines
R-HSA-933542: TRAF6 mediated NF-kB activation
R-HSA-975138: TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
R-HSA-937061: TRIF-mediated TLR3/TLR4 signaling
R-HSA-168142: Toll Like Receptor 10 (TLR10) Cascade
R-HSA-181438: Toll Like Receptor 2 (TLR2) Cascade
R-HSA-168164: Toll Like Receptor 3 (TLR3) Cascade
R-HSA-166016: Toll Like Receptor 4 (TLR4) Cascade
R-HSA-168176: Toll Like Receptor 5 (TLR5) Cascade
R-HSA-168181: Toll Like Receptor 7/8 (TLR7/8) Cascade
R-HSA-168138: Toll Like Receptor 9 (TLR9) Cascade
R-HSA-168179: Toll Like Receptor TLR1
R-HSA-168188: Toll Like Receptor TLR6
R-HSA-168898: Toll-Like Receptors Cascades
R-HSA-1606322: ZBP1(DAI) mediated induction of type I IFNs

Summary
Symbol	NFKB2
Name	nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100)
Aliases	LYT-10; NF-kB2; CVID10; H2TF1; LYT10; DNA-binding factor KBF2; NFKB, p52/p100 subunit; lymphocyte translocat ......
Chromosomal Location	10q24
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between NFKB2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between NFKB2 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
18281283	T-Cell Non-Hodgkin Lymphoma; Chronic Lymphocytic Leukemia; Plasma Cell Myeloma; Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma	Inhibit immunity	The NF-κB2 gene is recurrently mutated in a variety of human lymphoid malignancies, including T-cell lymphoma, chronic lymphocytic leukemia, multiple myeloma, and B cell lymphoma. However, they are predisposed to inflammatory autoimmune disease characterized by multiorgan infiltration of activated lymphocytes, high levels of autoantibodies in the serum, and immune complex glomerulonephritis. p52, but not p80HT, represses Bim expression, leading to defects in apoptotic processes critical for elimination of autoreactive lymphocytes and control of immune response. These findings reveal distinct signaling pathways for actions of NF-kappaB2 mutants and p52 and suggest a causal role for sustained NF-kappaB2 activation in the pathogenesis of autoimmunity.

Summary
Symbol	NFKB2
Name	nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100)
Aliases	LYT-10; NF-kB2; CVID10; H2TF1; LYT10; DNA-binding factor KBF2; NFKB, p52/p100 subunit; lymphocyte translocat ......
Chromosomal Location	10q24
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of NFKB2 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	NFKB2
Name	nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100)
Aliases	LYT-10; NF-kB2; CVID10; H2TF1; LYT10; DNA-binding factor KBF2; NFKB, p52/p100 subunit; lymphocyte translocat ......
Chromosomal Location	10q24
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of NFKB2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.051	0.875
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.043	0.983
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.118	0.935
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.115	0.796
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.114	0.962
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.41	0.899
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.529	0.2
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.505	0.719
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.53	0.741
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.795	0.632
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.674	0.785
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.098	0.253

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of NFKB2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	0	7.1	0.452
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	0	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	11.1	4.1	7	0.339
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	11.1	5.1	6	0.373
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	5.3	0	5.3	0.507
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	0	6.2	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	NFKB2
Name	nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100)
Aliases	LYT-10; NF-kB2; CVID10; H2TF1; LYT10; DNA-binding factor KBF2; NFKB, p52/p100 subunit; lymphocyte translocat ......
Chromosomal Location	10q24
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NFKB2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	NFKB2
Name	nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100)
Aliases	LYT-10; NF-kB2; CVID10; H2TF1; LYT10; DNA-binding factor KBF2; NFKB, p52/p100 subunit; lymphocyte translocat ......
Chromosomal Location	10q24
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NFKB2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NFKB2. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	NFKB2
Name	nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100)
Aliases	LYT-10; NF-kB2; CVID10; H2TF1; LYT10; DNA-binding factor KBF2; NFKB, p52/p100 subunit; lymphocyte translocat ......
Chromosomal Location	10q24
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NFKB2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	NFKB2
Name	nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100)
Aliases	LYT-10; NF-kB2; CVID10; H2TF1; LYT10; DNA-binding factor KBF2; NFKB, p52/p100 subunit; lymphocyte translocat ......
Chromosomal Location	10q24
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of NFKB2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	NFKB2
Name	nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100)
Aliases	LYT-10; NF-kB2; CVID10; H2TF1; LYT10; DNA-binding factor KBF2; NFKB, p52/p100 subunit; lymphocyte translocat ......
Chromosomal Location	10q24
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between NFKB2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	NFKB2
Name	nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100)
Aliases	LYT-10; NF-kB2; CVID10; H2TF1; LYT10; DNA-binding factor KBF2; NFKB, p52/p100 subunit; lymphocyte translocat ......
Chromosomal Location	10q24
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting NFKB2 collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting NFKB2.

ID	Name	Drug Type	Targets	#Targets
DB00945	Acetylsalicylic acid	Small Molecule	AKR1C1, EDNRA, HSPA5, IKBKB, NFKB1, NFKB2, NFKBIA, PRKAA1, PRKAA2, ......	18
DB01296	Glucosamine	Small Molecule	IFNG, MMP9, NFKB2, TNF	4
DB05212	HE3286	Small Molecule	NFKB1, NFKB2	2
DB05451	P54	Small Molecule	NFKB1, NFKB2	2
DB05464	NOX-700	Small Molecule	NFKB1, NFKB2	2
DB05471	SGN-30	Biotech	NFKB1, NFKB2	2
DB05487	Custirsen	Small Molecule	ESR1, NFKB1, NFKB2	3
DB05767	Andrographolide	Small Molecule	IL1B, IL6, NFKB1, NFKB2, TNF	5

Browse NFKB2